FindTrial
Sign In

Placlitaxel

DRUG2 trials

Sponsors

Sanofi, Fundación GECP

Conditions

Carcinoma Bronchiogenic Stage IIICarcinoma, Non-Small-Cell LungLung DiseasesNeoplasm MalignantRespiratory Tract NeoplasmsStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerThoracic Neoplasms

Phase 1

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
CompletedNCT01455532
SanofiNeoplasm Malignant
Start: 2011-11-30End: 2014-04-30Updated: 2014-10-22

Phase 2

Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
CompletedNCT04776447
Fundación GECPCarcinoma Bronchiogenic Stage III, Carcinoma, Non-Small-Cell Lung, Lung Diseases +4
Start: 2021-06-16End: 2025-07-31Updated: 2026-07-22

Related Papers

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.
2025-12-23
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non–Small Cell Lung Cancer: The Induction Trial
Clinical Cancer Research2025-01-172 citations
Abstract C242: A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors.
Molecular Cancer Therapeutics2013-11-01